Ocrelizumab reduces progression of brain atrophy in patients with multiple sclerosis
Introduction: Multiple sclerosis (MS) is a clinical entity characterised by both inflammatory and neurodegenerative components. Ocrelizumab is an anti-CD20 monoclonal antibody that has demonstrated high clinical efficacy in controlling neuroinflammation, and evidence suggests it may also exert a ben...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2026-04-01
|
| סדרה: | Neurology Perspectives |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S2667049625000341 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|